Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyle Fahrbach

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
Journal of Comparative Effectiveness Research|July 29, 2023
Handling related publications reporting real-world evidence in network meta-analysis: a case study in multiple sclerosisMarissa Betts, Kyle Fahrbach, Binod Neupane, et al.
Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies|January 5, 2011
Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysisPaul A Checchia, Luba Nalysnyk, Ancilla W Fernandes, et al.
Cardiovascular Drugs and Therapy|March 16, 2012
Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillationLori D Bash, Jessica L Buono, Glenn M Davies, et al.
Advances in Therapy|May 30, 2019
Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic LeukemiaIrina Proskorovsky, Yun Su, Kyle Fahrbach, et al.
Dermatology and Therapy|November 1, 2024
Long-Term Efficacy and Safety of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: Updated Systematic Literature Review and Network Meta-analysisRichard B Warren, Kerry Donnelly, Sandeep Kiri, et al.
Current Medical Research and Opinion|March 9, 2022
Comparative efficacy of non-statin lipid-lowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: a network meta-analysisHeather Burnett, Kyle Fahrbach, Allie Cichewicz, et al.
The American Journal of Medicine|March 11, 2009
Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysisHenry Buchwald, Rhonda Estok, Kyle Fahrbach, et al.
Toxins|November 10, 2022
AbobotulinumtoxinA Doses in Upper and Lower Limb Spasticity: A Systematic Literature ReviewAlexis Schnitzler, Clément Dince, Andreas Freitag, et al.
Journal of Cardiovascular Pharmacology|May 13, 2025
Comparative Efficacy of Non-Statin Lipid-Lowering Therapies in Patients With Hypercholesterolemia at Increased Cardiovascular Risk: An Updated Network Meta-AnalysisHeather Burnett, Allie Cichewicz, Harshul Natani, et al.
BMJ Open Diabetes Research & Care|May 4, 2021
Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular diseaseOdette S Reifsnider, Anuraag R Kansal, Pranav K Gandhi, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Journal of Comparative Effectiveness Research|July 29, 2023
Handling related publications reporting real-world evidence in network meta-analysis: a case study in multiple sclerosisMarissa Betts, Kyle Fahrbach, Binod Neupane, et al.
Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies|January 5, 2011
Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysisPaul A Checchia, Luba Nalysnyk, Ancilla W Fernandes, et al.
Cardiovascular Drugs and Therapy|March 16, 2012
Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillationLori D Bash, Jessica L Buono, Glenn M Davies, et al.
Advances in Therapy|May 30, 2019
Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic LeukemiaIrina Proskorovsky, Yun Su, Kyle Fahrbach, et al.
Dermatology and Therapy|November 1, 2024
Long-Term Efficacy and Safety of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: Updated Systematic Literature Review and Network Meta-analysisRichard B Warren, Kerry Donnelly, Sandeep Kiri, et al.
Current Medical Research and Opinion|March 9, 2022
Comparative efficacy of non-statin lipid-lowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: a network meta-analysisHeather Burnett, Kyle Fahrbach, Allie Cichewicz, et al.
The American Journal of Medicine|March 11, 2009
Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysisHenry Buchwald, Rhonda Estok, Kyle Fahrbach, et al.
Toxins|November 10, 2022
AbobotulinumtoxinA Doses in Upper and Lower Limb Spasticity: A Systematic Literature ReviewAlexis Schnitzler, Clément Dince, Andreas Freitag, et al.
Journal of Cardiovascular Pharmacology|May 13, 2025
Comparative Efficacy of Non-Statin Lipid-Lowering Therapies in Patients With Hypercholesterolemia at Increased Cardiovascular Risk: An Updated Network Meta-AnalysisHeather Burnett, Allie Cichewicz, Harshul Natani, et al.
BMJ Open Diabetes Research & Care|May 4, 2021
Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular diseaseOdette S Reifsnider, Anuraag R Kansal, Pranav K Gandhi, et al.
Pageof 6